High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy

BACKGROUND: The high prevalence of type 2 diabetes mellitus (DM) among patients with colorectal cancer (CRC) is becoming a serious public health concern worldwide. FOLFOX4 chemotherapy is one of the most widely used adjuvant therapies in patients with stage III colon cancer after surgical resection....

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, I-Ping, Miao, Zhi-Feng, Huang, Ching-Wen, Tsai, Hsiang-Lin, Yeh, Yung-Sung, Su, Wei-Chih, Chang, Tsung-Kun, Chang, Se-fen, Wang, Jaw-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704420/
https://www.ncbi.nlm.nih.gov/pubmed/31467597
http://dx.doi.org/10.1177/1758835919866964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704420/
https://www.ncbi.nlm.nih.gov/pubmed/31467597
http://dx.doi.org/10.1177/1758835919866964

Ejemplares similares